DactinomycinThird Party Manufacturing in India

Dactinomycin works by binding to DNA and blocking the synthesis of RNA within rapidly dividing cancer cells.

The molecule intercalates itself into the DNA double helix, specifically binding to guanine-cytosine base pairs. This physical insertion alters the shape of the DNA template and blocks the movement of DNA-dependent RNA polymerase, thereby halting the transcription of messenger RNA. Consequently, the cell cannot produce proteins necessary for survival and division. At higher clinical concentrations, dactinomycin also inhibits DNA replication and impairs topoisomerase II, leading to DNA strand breaks and apoptosis.

Unlike synthetic chemical chemotherapy agents, Dactinomycin is a naturally derived polypeptide antibiotic that acts as a potent cell-cycle non-specific cytotoxic drug. It is highly effective for pediatric oncology patients undergoing combination treatments.

Dactinomycin (CAS 50-76-0) is an essential cytotoxic antibiotic used in multiple pediatric and adult cancer regimens. We offer high-quality options for Dactinomycin third party manufacturing in India, ensuring stable global access to this critical antineoplastic drug.

Therapeutic Uses

Dactinomycin is prescribed for the treatment of:

• Wilms' Tumor: Used in combination chemotherapy regimens as standard treatment for pediatric nephroblastoma.
• Rhabdomyosarcoma: Indicated for pediatric soft-tissue tumors, usually combined with vincristine and cyclophosphamide.
• Gestational Trophoblastic Neoplasia: Prescribed as a first-line treatment for low-risk and high-risk gestational trophoblastic tumors.
• Ewing's Sarcoma: Utilized in multi-agent chemotherapy regimens to treat malignant bone tumors in children and young adults.

Choosing a Dactinomycin Manufacturer in India

Dactinomycin is listed on the WHO Model List of Essential Medicines due to its irreplaceable role in pediatric oncology. Because of its high potency, manufacturing dactinomycin injection requires highly specialized aseptic processing, lyophilization technology, and dedicated cytotoxic containment areas. Sourcing from a WHO-GMP certified manufacturer in India ensures that each vial contains sterile, pyrogen-free lyophilized powder meeting the strict requirements of IP, BP, and USP standards. Partnering with a WHO-GMP certified partner allows oncology distributors to secure a steady supply for hospital tender systems and international export markets.

To start a project, please contact our team today. You can view our comprehensive range of oncology injectables in our manufacturing listing or check our contract manufacturing page for details.

This makes Dactinomycin one of the most sought-after molecules for third party manufacturing in India, with consistent demand from pediatric oncology networks and export-oriented distributors.